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 ABSTRACT
Introduction. Diagnostic criteria for CIDP have been 
proven useful for clinical trials. However, use of these cri-
teria in clinics has been limited by time constraints and un-
known usefulness in predicting outcomes. 
Methods. A retrospective chart review of CIDP patients at 
the University of Kansas seen between 2008 and 2014 was 
performed. We determined the diagnostic criteria fulfilled 
by each patient and assessed treatment responses. A posi-
tive response was defined by improvement sensory or motor 
examination as determined by a neuromuscular physician.
Results. There were 38 total patients included in the study. 
The response rate to IVIG in patients who fulfilled EFNS/
PNS criteria was 20/22 (90.1%). Among patients who ful-
filled AAN criteria, 8/9 (88.9%) responded positively to 
IVIG. Slightly lower response rates were seen in patients 
fulfilling INCAT criteria and Saperstein criteria at 10/15 
(66.7%) and 12/17 (70.6%), respectively.
Discussion. EFNS/PNS and AAN criteria can similarly 
predict IVIG treatment response.  
Keywords: Chronic Inflammatory Demyelinating Polyneu-
ropathy, Retrospective Chart Review, Diagnostic Criteria, 
Treatment Response, IVIG, EFNS/PNS.
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy 
is known to be an immune-mediated peripheral neuropathy, 
but the precise pathogenesis has yet to be fully elucidated.1 
It is a relatively rare disease with an estimated prevalence 
of 4.7 per 100,000 adults.2 Although the “typical” form of 
CIDP presents clinically with symmetric, proximal and 
distal weakness, hypo- or areflexia, and mainly large fiber 
sensory loss, there is a large range of clinical heterogeneity 
in the disease.3 Various diagnostic criteria have been devel-
oped to help diagnose this condition in clinical and research 
settings including AAN, Saperstein, INCAT, and EFNS/
PNS. Currently, the most commonly used, especially in re-
search settings, is the EFNS/PNS criteria that was devel-
oped in 2010. 
The major highlights of the diagnostic criteria that 
were used in this study are reviewed in Table 1. Generally 
speaking, all of the criteria rely on clinical, electrophysiolog-
ical, and supportive studies to make the diagnosis of CIDP. 
Additionally, disorders that may appear similarly to CIDP 
Table 1: Major clinical and diagnostic features of various criteria.
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must be excluded. The major differences between the crite-
ria are in the electrophysiological parameters. For example, 
the AAN criteria tends to be more conservative in defining 
parameters of demyelination such as abnormal conduction 
velocity and prolonged distal latency compared to the other 
criteria. Furthermore, some criteria such as EFNS/PNS 
only require 1 out of 7 electrophysiological parameters be 
fulfilled to meet diagnostic standards while AAN requires 
3 out of 4. 
At the present time, it is unclear whether or not these 
criteria have clinical applications beyond assisting in diag-
nosis. The goals of this study were to identify patients with a 
clinical diagnosis of CIDP who fulfilled the diagnostic crite-
ria under investigation and also determine whether fulfilling 
certain criteria had any implications in treatment response.
Methods
Using the Neuromuscular database at the University 
of Kansas Hospital, we searched for ICD-9 and PNS codes 
specific for CIDP. Using this method, we identified 53 po-
tential patients for the study. Following identification, we 
collected patient data from the clinical record including 
date of diagnosis, clinical presentation, nerve conduction 
study data, initial treatment, and clinical response to the 
initial treatment. Data was collected from the initial patient 
visit at the time of diagnosis and the initial follow-up after 
therapy. Using this information, we were able to determine 
which patients fulfilled EFNS/PNS, INCAT, Saperstein, 
or AAN diagnostic criteria. We subsequently determined 
whether or not these patients responded to the initial treat-
ment that was given. Treatment response was defined by 
improvement in sensory or motor examination as deter-
mined during initial follow-up by the examining neuromus-
cular physician.
Patient Characteristics
There were a total of 53 patients identified for potential 
inclusion in the study based on our data search. After initial 
data collection, 15 patients were excluded leaving 38 who 
were ultimately included in the study. Of those excluded, 
10 patients did not have a formal diagnosis of CIDP by a 
neuromuscular physician and five had insufficient data in 
the records to assess which diagnostic criteria they fulfilled 
(Figure 1).
The male to female ratio of those included in the study 
was 22 to 16. The age range at diagnosis was 17 to 81 years 
(mean 51.5, SD ± 12.9). Of the 23 patients who had CSF 
data available, 78% had elevated CSF protein without pleo-
cytosis. 
Diagnostic Criteria
A basic overview of the requirements for each diagnos-
tic criteria we assessed is provided in Table 1. A total of 28 
of our patients fulfilled the “Definite” EFNS/PNS criteria 
(73.68%) and another five fulfilled the “Probable” EFNS/
PNS criteria (13.16%). Saperstein and INCAT criteria were 
fulfilled by 20 patients each (52.6%), and ten patients ful-
filled the criteria proposed by AAN (26.3%). Of the 25 pa-
tients who fulfilled multiple criteria, seven fulfilled all of the 
diagnostic criteria under investigation. All of the patients 
that fulfilled either the AAN, Saperstein, or INCAT crite-
ria also fulfilled the EFNS/PNS criteria, and eight patients 
fulfilled the EFNS/PNS criteria alone. All but five patients 
fulfilled at least one of the diagnostic criteria. (Figure 2) 
Treatment Response
A complete representation of response rates to vari-
ous therapies in our study is provided in Table 2. A positive 
treatment response was defined by improvement in motor 
or sensory examination as determined during initial fol-
low-up by a neuromuscular physician. The median time to 
follow-up at which treatment response was assessed was 6 
months. A total of 29 patients in our study received IVIG as 
an initial therapy. Of those patients, 22 responded positively 
(75.9%). Of those who met EFNS/PNS criteria, 20 out of 
22 patients had a positive response (90.1%), and patients 
who fulfilled AAN criteria responded at a similar rate of 
88.9%. Patients fulfilling Saperstein criteria responded at a 
rate of 70.6%, and 66.7% of the INCAT patients responded 
favorably. Response rates for those receiving steroids were 
slightly lower overall when compared to IVIG. A total of 
9 patients received steroids and 6 of those patients had a 
Figure 1: Patient Entry Criteria
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positive response. Of those meeting EFNS/PNS criteria, 
five out of 8 responded favorably (62.5%). Similar numbers 
were seen for those meeting AAN (66.7%), INCAT (71.4%) 
and Saperstein (50%) criteria. The time to follow-up at 
which treatment response was measured ranged from one 
to 29 months (mean 7.5 months, SD ± 6.8). 
Discussion
The diagnostic criteria under investigation in this study 
have varying sensitivities and specificities4. A retrospective 
study by Breiner in 2014 showed that the 2010 EFNS/PNS 
definite criteria had a sensitivity of 73.2% and a specificity 
of 88.2% which is favorable compared to other diagnostic 
criteria for CIDP4. The relatively high sensitivity of the 
EFNS/PNS criteria is consistent with the findings of this 
study as the majority of our patients fulfilled this criteria. 
Conversely, the AAN criteria has a specificity of 100%, but 
the sensitivity for possible CIDP is only 25%.4 This is also 
consistent with our findings as a much smaller percentage 
of our patients fulfilled the AAN criteria. 
The ICE trial, a randomized placebo controlled study, 
demonstrated the efficacy of IVIG in patients with CIDP.5 
This trial used the INCAT diagnostic criteria for inclusion 
in the study and found that 54% had functional improve-
ment in the INCAT disability score during the first 24 weeks 
of treatment IVIG.5 A more recent phase III trial published 
in 2017 by Kuwabara et al. found that 77.8% of patients had 
improvement in INCAT disability scores when treated with 
IVIG after 28 weeks of therapy.6 In contrast to the ICE tri-
al, patients in the Kuwabara et al. study fulfill the EFNS/
Table 2: Comparison of treatment responses of patients fulfilling various CIDP criteria.
Figure 2: Number of patients fulfilling each criterion.
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PNS definite or probable criteria prior to enrollment. Our 
findings were consistent with the data in these trials in that 
patients fulfilling the EFNS/PNS criteria in our study re-
sponded at a higher rate (90.1%) than those fulfilling the 
INCAT criteria (66.7%). The slightly higher response rates 
seen in our study compared to previous trials may be related 
to differences in outcome measures. 
Prior to this study, there was limited data comparing 
the treatment responses of patients fulfilling different diag-
nostic criteria for CIDP. This information has clinical signif-
icance in that it may help predict outcomes in patients with 
this condition. Using the results of this study in conjunction 
with previous studies on the sensitivity and specificity data 
of these criteria, it could be argued that neurologists should 
use the EFNS/PNS criteria when predicting treatment 
response for patients with CIDP. The high sensitivity and 
specificity of the EFNS/PNS criteria along with the rela-
tively high treatment response rates seen in this study sug-
gest that it may be favorable to other diagnostic criteria in 
clinical settings. Patients who fulfill the EFNS/PNS criteria 
appear to have equal or superior treatment response rates 
compared to patients fulfilling more specific criteria, such 
as those proposed by the AAN, suggesting little clinical ben-
efit when using the most specific diagnostic criteria. 
Limitations of this study include its retrospective na-
ture and the descriptive statistical analysis used to compare 
treatment responses. In addition to this limitation, it should 
be noted that data was only obtained from two time points, 
and although the median time to follow-up was 6 months, 
there was considerable variation between patients. Future 
studies should include long-term follow-up data to deter-
mine whether or not initial response rates predict clinical 
stability or future response to therapy. Furthermore, our 
study used an “all-or-none” approach when determining 
patient response to therapy, so there may be significant 
variability in functional outcomes even between patients 
with a positive response. Using tools utilized in other stud-
ies such as the INCAT disability score would be helpful in 
assessment of the degree of improvement between patient 
subsets and would allow for easier comparison with previ-
ous studies. 
In conclusion, this study provides information on some 
of the diagnostic criteria used for CIDP and a possible re-
lationship with these criteria to treatment responsiveness. 
Despite differences in sensitivities and specificities, the re-
sponse rates to IVIG appear to be similar for those meet-
ing AAN and EFNS/PNS criteria. Additional studies that 
have longer follow-up and that use a functional outcome 
measures to stratify treatment responsiveness are needed 
to support these findings.
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